Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are composed of recommendations based on the best evidence available at the time they are derived. Because new data are published continuously, the NCCN Guidelines® also are continuously updated and revised to reflect evolving data. The goal of the NCCN Guidelines is to help oncologists and other oncology health care professionals make the major clinical decisions encountered in managing their patients by providing ready access to the highest quality information available based on the evaluation of expert clinicians from NCCN Member Institutions.
The NCCN Guidelines provide recommendations for appropriate care for about 95% of patients; however, individual patient circumstances must be considered when applying these recommendations. In all cases, clinicians need to be aware of the current clinical status of the patient, including general health, disease specifics, personal preference, and current and former therapies. Once the current state of the patient is known, multidisciplinary considerations, partnered with the standards of care, can be applied to each patient case. Each tumor type has specific recommendations to be considered by the multidisciplinary team.
Tumor boards provide a forum for a multidisciplinary team of experts to review the clinical considerations and patient circumstances that influence how to effectively apply appropriate standard of care and specific recommendations in the NCCN Guidelines to optimize management of patients with various cancer types.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
The goal of this project is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the management of patients with cancer.
Upcoming topics for 2024:
- Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer
- Management of Early-Stage Non-Small Cell Lung Cancer
- Systemic Therapy for Metastatic Prostate Cancer
- Management of Pheochromocytoma and Paraganglioma
- B-Cell Lymphomas: Histologic Transformation of Indolent Lymphomas
- Updates in Treatment of Hairy Cell Leukemia
ALL WEBINAR TIMES ARE POSTED AS EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through the NCCN WebEx Site on the day of each scheduled program.
The most recent recorded webcasts from this series are listed below. Recordings from the previous NCCN Monthly Oncology Tumor Board series can be found here.
- Advances in Systemic Treatment of Metastatic Cutaneous Melanoma (presented June 23, 2023, by Douglas B. Johnson, MD, MSCI, Vanderbilt-Ingram Cancer Center, Colleen McCabe, PharmD, BCOP, and Elizabeth Gray Ryan, DNP, FNP-BC, Vanderbilt University Medical Center)
- Treatment of Deficient Mismatch Repair or Microsatellite Instability-High (dMMR/MSI-H) Colorectal Cancer (presented August 14, 2023, by Michael Bassetti, MD, PhD; Evie Carchman, MD; and Dustin A. Deming, MD, University of Wisconsin Carbone Cancer Center)
- Management of Thyroid Carcinomas (presented September 25, 2023, by Lori J. Wirth, MD; Giuseppe Barbesino, MD; and Carrie Cunningham, MD, MPH, Mass General Cancer Center)
- Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma (presented October 17, 2023, by Eric Jonasch, MD; Nicolas Palaskas, MD; and Yinghong (Mimi) Wang, MD, PhD, The University of Texas MD Anderson Cancer Center)
- Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix (presented November 30, 2023, by Nadeem R. Abu-Rustum, MD; Claire F. Friedman, MD; and Latasha Anderson-Dunkley, MSN, ANP-BC, Memorial Sloan Kettering Cancer Center)
- Management of Advanced Ovarian Cancer (presented on December 6, 2023, by Deborah K. Armstrong, MD, and Carol D. Riley, RN, MSN, CRNP, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, case managers, and other health care professionals. Complete accreditation information is provided before each individual educational activity.
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing